Clinical Trial Update: Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Gadavist (gadobutrol) as an MRI contrast agent for vascular diseases in Chinese patients has been completed and results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vascular Diseases

Drugs mentioned

• Gadavist (gadobutrol)

Snippet

Sponsor: Bayer | Conditions: Vascular Diseases | Phase 3 | Status: COMPLETED | Results posted: 2011-08-03